The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much ...

Semaglutide belongs to a class of prescription medications that mimic a hormone your body naturally produces after you eat. This hormone helps your pancreas make insulin, which lowers your blood sugar ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

BOSTON - There is concern over the newest weight loss drugs sparking eating disorders in teens. Newer GLP-1 weight loss drugs ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...

The effectiveness can vary based on the individual response and adherence to treatment. Research indicates that GLP-1 ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

With 890 million people affected globally and 42% of American adults classified as obese, the allure of a "miracle" weight ...

Semaglutide – a key ingredient in Ozempic and Wegovy – was associated with a lower risk of opioid overdose in patients with Type 2 diabetes and opioid use disorder, research shows.

The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...